Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Lymphoma, Lymphoma |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/13/2019 |
Start Date: | August 2013 |
End Date: | December 2019 |
Contact: | Portola Pharmaceuticals |
Email: | ClinicalTrials@portola.com |
Phone: | 650.246.7000 |
A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070)
that may be given in patients with relapsed/refractory chronic lymphocytic leukemia or
non-hodgkin lymphoma
that may be given in patients with relapsed/refractory chronic lymphocytic leukemia or
non-hodgkin lymphoma
This is an open-label, Phase 1/2a, multi dose, multi-center trial of orally administered
cerdulatinib assessing safety, tolerability and PK parameters conducted in 2 phases:
- Phase 1: Dose-escalation portion, during which 43 patients enrolled to receive a
single-agent cerdulatinib at their assigned dose level starting at 15 mg QD,
administered in increasing doses until the MTD/MAD is identified.
- Phase 2a: Consisting of 6 planned cohorts of up to 40 patients each by cancer type. Five
cohorts will receive single agent cerdulatinib at a starting dose of 30 mg BID for
28-day cycles. Cohort 2 receives cerdulatinib plus rituximab IV at 375 mg/m2.
cerdulatinib assessing safety, tolerability and PK parameters conducted in 2 phases:
- Phase 1: Dose-escalation portion, during which 43 patients enrolled to receive a
single-agent cerdulatinib at their assigned dose level starting at 15 mg QD,
administered in increasing doses until the MTD/MAD is identified.
- Phase 2a: Consisting of 6 planned cohorts of up to 40 patients each by cancer type. Five
cohorts will receive single agent cerdulatinib at a starting dose of 30 mg BID for
28-day cycles. Cohort 2 receives cerdulatinib plus rituximab IV at 375 mg/m2.
Inclusion Criteria:
Phase 1 Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or
B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma).
Phase 2a Inclusion
- Histological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL
includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL
with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or
refractory.
- Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease
afterwards.
- Prior treatment for lymphoid malignancy for progressive /refractory disease
- ≥ 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or
TKI alone or in combination.
- Measureable disease defined as: ≥ 1 lesion ≥ 1.5 cm single dimension via CT, CT/PET
with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenström's
macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0
- Ability to provide diagnostic reports
General Inclusion
- ECOG Score of 0 or 1.
- Hematologic ANC > 1000/uL and platelet > 75,000/uL,
- Serum creatinine of < 1.5 ULN or calculated CrCl of > 50 mL/min
- Bilirubin < 20.0mg/dL (if Gilberts then < 2.5 mg/dL) and AST/AST < 2.5 ULN
Exclusion Criteria:
- Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL
from Follicular NHL are eligible).
- Prior transplant with stem cell infusion 90 days or active graft-versus-host treatment
within 8 weeks of Day 1.
- Prior therapy with SYK inhibitors.
- Chronic treatment with strong CYP3A4 inhibitor/ inducer, acid reducing agent, Proton
pump inhibitors
- Known lymphomatous involvement of the CNS.
- Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity
(except alopecia, erectile impotence, hot flashes, libido, neuropathy).
- Prior monoclonal antibody, radioimmunoconjugate, antibody drug conjugate,
phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or
any test agent within 3 weeks or for alemtuzumab 8 weeks of Day 1.
- For CTCL: (TSEBT) within 12 weeks, or initiation of topical steroid, nitrogen mustard,
or topical retinoid within 2 weeks. (Stable topical ≥ 4 weeks prior to Day 1 allowed).
- Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be
HBsAg- or undetectable DNA
- Active infection requiring systemic treatment,
- Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or
malabsorption syndrome.
- Major surgery within 4 weeks
- Previous malignancies within 2 yrs. unless relapse risk is small (< 5%).
- Current use of systemic steroids >20 mg QD prednisone (or equivalent)
- Breastfeeding or pregnant (intention to become) females or participation in other
clinical trials
We found this trial at
29
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials